Venus Remedies Secures In-Licensing Rights to Develop, Commercialize MET-X in India

MT Newswires Live
02-25

Venus Remedies (NSE:VENUSREM, BOM:526953) has secured exclusive in-licensing rights from UK-based anti-infectives specialist Infex Therapeutics to develop and commercialize MET-X in India, according to a Tuesday filing to the Indian stock exchanges.

Under the terms of the agreement, Venus Remedies will begin with the first phase involving healthy volunteers in lndia, evaluating MET-X in combination with meropenem.

Following this, the focus will shift to the second and third phase trials targeting drug resistant complicated urinary tract infections in prevalent hospital settings.

Shares of the company were up 2% in recent trade.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10